AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyPhase 3Trial registry
Long-term Safety and Efficacy of Ublituximab in Human Relapsing Multiple Sclerosis
This phase 3 study, TG1101-RMS303, is designed to assess the long-term safety and efficacy of ublituximab in participants with relapsing multiple sclerosis (RMS).
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
Understanding the long-term safety and efficacy of treatments like ublituximab is crucial for managing RMS, as it can help inform future treatment options.
What this does not prove
No results have been posted; the planned enrollment and endpoints mentioned are not actual findings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Interventional
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- RRMS
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
Supporting passages (7)
study phaseTG1101-RMS303 is an open-label, single-arm extension study designed to evaluate long-term safety and efficacy of ublituximab in participants with RMS.
study design"detailedDescription": "TG1101-RMS303 is an open-label, single-arm extension study designed to evaluate long-term safety and efficacy of ublituximab in participants with RMS.
subjects"briefSummary": "The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).",
relevant ms types"briefSummary": "The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).",
primary endpoint"description": "ARR is defined as the number of relapses per-participant year.
findingsThe purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
limitationsNo results are posted. Planned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.